Poland

Eli Lilly and Novo Nordisk Paid Doctors and Foundations Millions, Disclosures Show

Obesity drug makers Eli Lilly and Novo Nordisk, which market Mounjaro and Wegovy, gave about PLN 25 million in 2025 to doctors, universities, foundations and scientific societies. This is according to their transparency reports.

Where the data comes from

Companies belonging to the INFARMA association publish transparency reports on payments to healthcare professionals and healthcare organisations every year. Novo Nordisk makes them available on its website and states that it discloses data on specific individuals only with their consent. An analysis of these reports was published by “Rzeczpospolita”, which calculated the total for both companies.

Where the PLN 25 million went

According to this analysis, about PLN 16 million went to sponsorship agreements with scientific societies, universities, hospitals and patient organisations. Around PLN 9 million was paid as fees for services provided by medical professionals. These amounts do not include, among other things, funding for doctors’ trips to conferences.

The records show that in 2025 the Polish Diabetes Society received PLN 792 thousand from Eli Lilly and PLN 732 thousand from Novo Nordisk. The Polish Cardiac Society received PLN 665 thousand from Novo Nordisk. The Foundation for the Treatment of Obesity, established in 2023, received PLN 50 thousand from Novo Nordisk in 2024 and PLN 190 thousand in 2025. From Eli Lilly it received PLN 284 thousand in those years, respectively, and further amounts.

Anonymous payments

A doctor must consent to having their name and amount disclosed. If they do not, the company reports only aggregate data. In Eli Lilly’s report for 2025, this covers 348 people and about PLN 3 million, roughly eight in ten collaborating medical professionals. Novo Nordisk’s aggregate list includes 496 people and almost PLN 5 million.

Background: market and reimbursement

In 2025 Poles spent nearly PLN 1.5 billion on drugs registered for treating obesity: PLN 1.292 billion on Mounjaro and PLN 182 million on Wegovy. Including diabetes drugs used off-label, such as Ozempic and Rybelsus, the amount exceeds PLN 2 billion.

The manufacturers are seeking reimbursement. According to estimates cited by “Rzeczpospolita”, reimbursing Mounjaro would cost an additional about PLN 550 million over two years, and Wegovy about PLN 860 million over four years. The President of the Agency for Health Technology Assessment and Tariff System has so far not recommended reimbursement for either drug.

According to “Rzeczpospolita”, entities financed by the manufacturers also take part in events on obesity treatment held, among other places, in parliament, and the Ministry of Health reportedly has no legal basis to demand disclosure of experts’ financial ties during such debates. The sponsorship and fees themselves are public and consistent with industry code; no source indicates a breach of the law.

Dorota Lune

Dorota Lune, redaktorka serwisu DigitalNexus.pl. Zajmuje się tematyką show-biznesową, bieżącymi informacjami jak i ciekawostkami ze świata. Ukończyła dziennikarstwo na UPJPII w Krakowie. Wcześniej pracowała w branży turystycznej. W wolnych chwilach lubi podróżować i czytać książki.